Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters

Published:1996-08 Issue:4 Volume:24 Page:313-325
ISSN:0090-466X
Container-title:Journal of Pharmacokinetics and Biopharmaceutics
language:en
Short-container-title:Journal of Pharmacokinetics and Biopharmaceutics

Author:

Mummaneni Vanaja,Kaul Sanjeev,Igwemezie Linus N.,Newell David R.,Porter David,Thomas Huw,Calvert A. Hilary,Winograd Benjamin,Barbhaiya Rashmi H.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics

Link

http://link.springer.com/content/pdf/10.1007/BF02353515.pdf

Reference22 articles.

1. P. J. O'Dwyer, B. Leyland-Jones, M. T. Alonso, S. Marsoni, and R. E. Wittes. Etoposide (VP-16-213), Current status of an active anticancer drug.New Engl. J. Med. 312:692–699 (1985).

2. M. M. Hudson, H. J. Weinstein, S. S. Donaldson, C. Greenwald, L. Kun, N. J. Tarbell, W. A. Humphrey, C. Rupp, N. M. Marina, J. Wilimas, and M. P. Link. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease.J. Clin. Oncol. 11:1080–1084 (1993).

3. C. A. Linker, C. A. Ries, L. E. Damon, H. S. Rugo, and J. L. Wolf. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen.Blood 81:311–318 (1993).

4. A. M. Gianni, M. Bregni, S. Siena, M. Magni, M. De-Nicola, F. Lombardi, C. Tarella, A. Pileri, and G. Bonadonna. Granulocyte-macrophage colony stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.J. Clin. Oncol. 10:1955–1962 (1992).

5. N. J. Chao, A. S. Stein, G. D. Long, R. S. Negrin, M. D. Amylon, R. M. Wong, S. J. Forman, and K. G. Blume. Busulfan/Etoposide-Initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia.Blood 81:319–323 (1993).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unexpected acute renal injury after high-dose etoposide phosphate and total body irradiation in children undergoing hematopoietic stem cell transplantation;Pediatric Blood & Cancer;2017-07-11

2. Study to support the standardization of the prescribing, dispensing and labeling of etoposide formulations in Australia;Asia-Pacific Journal of Clinical Oncology;2010-07-23

3. High-performance liquid chromatographic methods for the determination of topoisomerase II inhibitors;Journal of Chromatography B: Biomedical Sciences and Applications;2001-11

4. Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients;Cancer Chemotherapy and Pharmacology;2001-08-01

5. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia;Leukemia;2001-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3